How can we optimize treatment of HER2-positive metastatic breast cancer?

Oncology (Williston Park). 2013 Mar;27(3):180, 182.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Female
  • Humans
  • Molecular Targeted Therapy*
  • Receptor, ErbB-2 / antagonists & inhibitors*

Substances

  • Antineoplastic Agents
  • Receptor, ErbB-2